Based on our findings, HDAC6 gain of function, either pharmacologically or through gene therapy–based ectopic expression of HDAC6 in cardiomyocytes, should be considered as an alternative or complementary approach to enhance titin compliance for the treatment of patients with DD. This evidence concerns the gene TTN and dentin dysplasia.